Turning Point Therapeutics Inc
Turning Point Therapeutics — Investor Presentation (January 2021)
33 slides from Turning Point Therapeutics's investor presentation, Jan 11, 2021
Slide 1: Next-Generation Precision Oncology Medicines Company Overview January 2021
Exhibit 99.1 Next-Generation Precision Oncology Medicines Company Overview January 2021Exhibit 99.1 Next-Generation Precision Oncology Medicines Company Overview January 2021
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development activities, plans and projected timelines, bus
Slide 3: Significant Pipeline Progress in 2020
Significant Pipeline Progress in 2020 ü Breakthrough Therapy Designation and Third FDA Fast Track Designation Granted ü Reported Early, Interim Data from TRIDENT-1 Phase 2 Registrational Study ü Continued Site Activation, ~90 Sites in 14 Countries in TRIDENT-1 Study Repotrectinib ü Received FDA Feed
Slide 4: Our Vision Drives Our Strategy to be a Leader in Precision Oncology
Our Vision Drives Our Strategy to be a Leader in Precision Oncology Clinical Research Commercial Development • Growing commercial team with • Deep expertise in tumor biology, and • Rapid clinical proof-of-concept data proven track record in oncology structure-based drug design • Oncology development
Slide 5: Strong Momentum Since IPO with Significant Pipeline Progress
Strong Momentum Since IPO with Significant Pipeline Progress $5.9 BILLION 2020 Year End $2.2 2019 $560 April 2019 BILLION Year End MILLION IPO • 3 clinical assets • 4 clinical studies • 3 clinical assets • Updated Phase 1 data and early Phase • 1 clinical asset (repotrectinib) 2 data for repotrectin
Slide 6: Lead Candidate Repotrectinib: Best-in-Class Potential in ROS1+ NSCLC
Lead Candidate Repotrectinib: Best-in-Class Potential in ROS1+ NSCLC 1 2 4 Repotrectinib Xalkori (Crizotinib) Rozlytrek (Entrectinib) TKI-Naïve TKI-Pretreated TKI-Naïve TKI-Naïve ROS1+ NSCLC (n=11) (n=7) (n=50) (n=161) 91% 57% 66% 67% Confirmed ORR (cORR) (95% CI: 59-100) (95% CI: 18 - 90) (95% CI:
Slide 7: Four Ongoing Clinical Studies Against Well Validated Oncogenic Targets
Four Ongoing Clinical Studies Against Well Validated Oncogenic Targets Multiple Additional Studies Anticipated in 2021 Early Stage Late Stage Clinical Clinical Discovery Preclinical Development Development Repotrectinib (ROS1/TRK) § TRIDENT-1: Advanced NSCLC (ROS1) and solid tumors (NTRK) § Pediatri
Slide 8: Single Agent and Combination Opportunities to Treat Biomarker Driven Cancers
Single Agent and Combination Opportunities To Treat Patients with Biomarker Driven Cancers Patient Populations: US+EU5 Incidence³ 4,5 ROS1+ NSCLC 6k 3.4 6 NTRK+ Solid Tumors 4k MILLION 4,7-8 MET Altered NSCLC 13k estimated patients diagnosed 9-12 MET Amplified Gastric Cancer 2k with solid tumors ann
Slide 9: Repotrectinib: A Highly Selective ROS1/TRK Inhibitor
Repotrectinib: A Highly Selective ROS1/TRK InhibitorRepotrectinib: A Highly Selective ROS1/TRK Inhibitor
Slide 10: Repotrectinib: Potential Best-in-Class ROS1 and NTRK Targeted Therapy
Repotrectinib: Potential Best-in-Class ROS1 and NTRK Targeted Therapy in TKI-Naïve and Treatment Resistance Settings § Highly potent, structurally differentiated: small (low Our Approach molecular weight), compact, with a rigid 3D Repotrectinib macrocycle ATP § Designed to bind completely inside the
Slide 11: Repotrectinib Selectivity Profile Potentially Expands Opportunity Beyond ROS1 and TRK
Repotrectinib Selectivity Profile Potentially Expands Opportunity Beyond ROS1 and TRK for Combinations Repotrectinib in Preclinical Models § Inhibits JAK2, SRC and FAK § Leads to suppression of STAT3 and AKT signaling, major mechanisms of resistance § Demonstrated synergy with AMG510, G12C inhibitin
Slide 12: Repotrectinib Enhances Survival with AMG510 in G12C KRAS Xenograft Model
G12C Repotrectinib Enhances Survival with AMG510 in NSCLC KRAS Xenograft Tumor Model H2122 Xenograft Model § Repotrectinib combination shows a significant survival benefit in NSCLC G12C KRAS xenograft model § Builds on prior preclinical studies showing synergy with AMG510, inhibiting G12C KRAS tumor
Slide 13: TRIDENT-1: Ongoing Phase 1/2 Study of Repotrectinib
TRIDENT-1: An Ongoing Phase 1/2 Study of Repotrectinib in Patients with Advanced Solid Tumors Harboring ROS1, NTRK1-3 Rearrangements Phase 2 Early Interim Update Based on Data Cutoff of July 10, 2020TRIDENT-1: An Ongoing Phase 1/2 Study of Repotrectinib in Patients with Advanced Solid Tumors Harbori
Slide 14: TRIDENT-1 Efficacy Overview – Early Phase 2 Data Compared to Phase 1
TRIDENT-1 Efficacy Overview – Early Phase 2 Data Compared to Phase 1 1 Phase 2 (N=39 ) Efficacy by Physician ROS1+ TKI-Naïve ROS1+ TKI Pretreated ROS1+ TKI Pretreated ROS1+ TKI Pretreated NTRK+ TKI-Pretreated Assessment (EXP-1: N=7) 1 Prior TKI with prior 1 Prior TKI without prior 2 Prior TKI withou
Slide 15: ROS1+ TKI Naïve Advanced NSCLC Patients
ROS1+ TKI Naïve Advanced NSCLC Patients EXP-1 + Phase 1 Phase 2 Phase 1+2 (n=7) (n=14) Confirmed ORR 86% 86% (42 – 100) (57 – 98) (95% CI) 0.9+ –2.0+ 0.9+ – 17.6+ months months Duration of Response (range) (range) n=6 n=12 ^Patient achieved an unconfirmed partial response after the data cutoff date
Slide 16: ROS1+ TKI-Pretreated Advanced NSCLC Patients
ROS1+ TKI-Pretreated Advanced NSCLC Patients EXP-2, 4, Other + Phase 1 Phase 2 Phase 1+2 40% 50% Confirmed ORR (5 – 85) (21 – 79) EXP-2: 1 Prior TKI (95% CI) n=5 n=12 with prior platinum 4.5 – 5.6+ 2.7+ – 11.1 Duration of months months chemotherapy (range) (range) Response n=2 n=6 67% 67% Confirmed
Slide 17: NTRK+ TKI-Pretreated Advanced Solid Tumor Patients in TRIDENT-1
NTRK+ TKI-Pretreated Advanced Solid Tumor Patients in TRIDENT-1 EXP-6 + Phase 1 Phase 2 Phase 1+2 (n=6) (n=7) Confirmed ORR 50% 43% (12 – 88) (10 – 82) (95% CI) 1.7+ – 3.6+ 1.7+ – 3.6+ months months Duration of Response (range) (range) n=3 n=3 Phase 2 Data cutoff of 10 July 2020, responses confirmed
Slide 18: Safety Summary: Treatment-Emergent and Treatment-Related AEs
Phase 2 Safety Summary: Treatment-Emergent and Treatment-Related AEs All Treated Patients (n=39) § Generally well-tolerated TEAEs (≥10% of patients) TRAEs § Most treatment emergent adverse events All Grades Grade 3 Grade 4 Grade 3¹ Grade 4 (TEAEs) and treatment-related adverse Adverse Event n (%) n
Slide 19: TRIDENT-1 Study Design
Phase 2 TRIDENT-1 Study Design ROS1+ Advanced NSCLC NTRK+ Advanced Solid Tumors EXP-1 EXP-2 EXP-3* EXP-4 EXP-5 EXP-6 ROS1 1 Prior ROS1 TKI 2 Prior ROS1 TKIs 1 Prior ROS1 TKI TRK TRK TKI-Naïve AND AND AND TKI-Naive TKI-Pretreated 1 Platinum-Based No Prior No Prior Chemotherapy Chemotherapy Chemothera
Slide 20: Advancing Three Additional Next-Generation Kinase Inhibitors
Advancing Three Additional Next-Generation Kinase InhibitorsAdvancing Three Additional Next-Generation Kinase Inhibitors
Slide 21: TPX-0022 is a Potent Inhibitor of MET, SRC, and CSF1R Tyrosine Kinases
TPX-0022 is a Potent Inhibitor of MET, SRC, and CSF1R Tyrosine Kinases § TPX-0022 is a potent MET inhibitor in both biochemical § TPX-0022 is highly selective for and cellular assays MET/SRC/CSF1R in a screen of 373 kinases Biochemical IC (nM) Cell Proliferation IC (nM) 50 50 Inhibitor MET SNU-5 MKN
Slide 22: SHIELD-1 Phase 1 Study of TPX-0022 in Advanced Solid Tumors
SHIELD-1 Phase 1 Study of TPX-0022 in Patients With Advanced Solid Tumors Harboring Genetic Alterations in MET Dose Escalation (n=22) Dose Expansion Patients enrolled as of 15-Oct 2020 Population NSCLC Exon 14 Deletion Investigating 40 mgà80 mg and 80 mgà120 mg titration regimens TKI-Naive § Adults
Slide 23: TPX-0022: Preliminary PK Summary
TPX-0022: Preliminary PK Summary Steady State Single Dose 1000 1000 100 100 120 mg, SS (mean ± sd, n=1) 10 80 mg, SS (mean ± sd, n=4) 10 120 mg, SD (mean ± sd, n=3) 40 mg, SS (mean ± sd, n=6) Cellular IC : 1.8 ng/mL 80 mg, SD (mean ± sd, n=4) 20 mg, SS (mean ± sd, n=3) 95 40 mg, SD (mean ± sd, n=8)
Slide 24: TPX-0022: Subject Disposition from SHIELD-1 Phase 1
TPX-0022: Subject Disposition from SHIELD-1 Phase 1 Early, Interim Data Data Presented at 2020 EORTC-NCI-AACR Symposium in October 2020 N=22 Enrolled Patients 13 NSCLC, 4 CRC, 4 Gastric, 1 Glioblastoma N=15 a Evaluable Patients TKI-Naïve (N=10) TKI-Pretreated 3 NSCLC, 4 CRC, (N=5) 3 Gastric 5 NSCLC
Slide 25: TPX-0022 Preliminary Safety Summary
TPX-0022 Preliminary Safety Summary All Treated Patients (n=21) § TPX-0022 has been generally well tolerated TEAEs (≥20% of patients) TRAEs § Most AEs were Grade 1 or 2 ^ All Grades Grades≥3 All Grades Grades≥3 Adverse Events§ Most common TEAE was dizziness, likely due to off n (%) n (%) n (%) n (%)
Slide 26: TPX-0022: Preliminary Efficacy by Investigator Assessment
TPX-0022: Preliminary Efficacy by Investigator Assessment from Dose Finding Study Tumor Assessment 50 PD 40 PD 30§ Of 10 MET TKI-Naïve patients, 5 have PD achieved PRs SD 20 PD PD – 3 gastric/GE junction, 1 CRC, and 1 10 NSCLC 40 80 40 120 80 80 40 120 40 0 • 3 cPRs are ongoing with DOR 40 20 40 20
Slide 27: TPX-0022 Duration of Treatment
TPX-0022 Duration of Treatment 40 u 40 80 u 20 80 u 40 u 40 Duration of Treatment 120 u NSCLC (N=8): 3.4 to 34+ weeks 20 CRC (N=4): 5.1 to 17 weeks 40 GC/GEJ (N=3): 9.4+ to 23.6+ weeks 40 MET ex14 NSCLC MET ex14 NSCLC 80 MET AMP NSCLC MET AMP NSCLC MET ex14 CRC 120 Legend u MET Fusion CRC MET Fusion
Slide 28: TPX-0022 SHIELD-1 Phase 1 Early, Interim Data Key Takeaways
TPX-0022 SHIELD-1 Phase 1 Early, Interim Data Key Takeaways § Encouraging Early Initial Data in Ongoing Phase 1 SHIELD-1 Study § TPX-0022 was generally well tolerated among 21 treated patients with 1 DLT at 120 mg QD^ § Preliminary Phase 1 data suggest pan-tumor potential – Responses observed in MET
Slide 29: TPX-0046: Highly Potent, Selective RET Inhibitor
TPX-0046: Highly Potent, Selective RET Inhibitor TPX-0046 § Comparable potency against WT RET to proxy chemical compounds of other RET agents¹ Differentiation § Rationally designed to address resistance from solvent front mutations § Non-small cell lung, medullary thyroid, papillary thyroid, and oth
Slide 30: TPX-0046 Phase 1/2 Study Ongoing
TPX-0046 Phase 1/2 Study Ongoing Phase 1 Dose Escalation Phase 2 (n=~40)¹ (n= ~300) RET Fusion+ NSCLC 1 RET TKI-Naïve RET Fusion+ NSCLC 2 1 Prior RET TKI Treated § Adult advanced solid tumor patients with RET genetic alterations (mutations RET Mutation+ Medullary Thyroid Carcinoma 3 or fusions) RET
Slide 31: TPX-0131: Highly Potent, Selective ALK Inhibitor
TPX-0131: Highly Potent, Selective ALK Inhibitor TPX-0131 § Potently inhibit WT ALK and solvent front / compound mutations Differentiation § Solvent front mutation G1202R reported in ~42% of patient biopsies with a resistance mutation¹ § ALK+ NSCLC and other solid tumors Target Population § IND subm
Slide 32: Anticipated Milestones
§ Report updated Phase 2 TRIDENT-1 data in TKI-Naïve ROS1+ Jan. 2021 NSCLC patients at the World Conference on Lung Cancer¹ § Provide update on overall Phase 2 TRIDENT-1 study timeline Q1 2021 Repotrectinib § Initiate Phase 2 TRIDENT-2 combination study in KRAS Mid 2021 Anticipated mutant NSCLC § Pr
Slide 33: Next-Generation Precision Oncology Medicines Company Overview January 2021
Next-Generation Precision Oncology Medicines Company Overview January 2021Next-Generation Precision Oncology Medicines Company Overview January 2021
Turning Point Therapeutics — Investor Presentation (January 2021) on 6ix